Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2 Recruiting
153 enrolled
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 3 Recruiting
222 enrolled
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Phase 1/2 Recruiting
281 enrolled
CAVALRY
Phase 1/2 Recruiting
104 enrolled
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Phase 2 Recruiting
60 enrolled
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Phase 2 Recruiting
128 enrolled
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Phase 1 Recruiting
20 enrolled
GRAALL-2024
Phase 2/3 Recruiting
1,200 enrolled
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Phase 1/2 Recruiting
104 enrolled
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Phase 2 Recruiting
78 enrolled
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 1/2 Recruiting
40 enrolled
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Phase 1/2 Recruiting
90 enrolled
Interfant-21
Phase 3 Recruiting
160 enrolled
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Phase 1 Recruiting
30 enrolled
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Phase 2 Recruiting
53 enrolled
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
Phase 2 Recruiting
80 enrolled
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Phase 1 Recruiting
242 enrolled
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Phase 1 Recruiting
40 enrolled
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Phase 2 Recruiting
27 enrolled
CAMS-Ph+ B-ALL
Phase 3 Recruiting
150 enrolled
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Phase 3 Recruiting
6,430 enrolled
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
Phase 2 Recruiting
26 enrolled
CCCG-LR-B-ALL
Phase 2/3 Recruiting
3,000 enrolled
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
Phase NA Recruiting
114 enrolled
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Phase 3 Recruiting
5,000 enrolled
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
Phase 2 Recruiting
20 enrolled
Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
Phase 2 Recruiting
30 enrolled
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Phase 2 Recruiting
20 enrolled
BEAT-ALL-2024
Phase 2 Recruiting
124 enrolled
MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients
Phase NA Recruiting
200 enrolled
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
Phase 2 Recruiting
20 enrolled